[1]
L. María Pellecchia and F. J. Manuel Correa, “Comparison of clinical efficacy and dosing regimens between Nirsevimab and Palivizumab for prophylaxis against RSV in the pediatric population”, SAP Primary Care, vol. 1, p. 18, Dec. 2025, doi: 10.62486/pc202518.